Ovid Therapeutics (OVID) Competitors

uniQure (NASDAQ:QURE) and Ovid Therapeutics (NASDAQ:OVID) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, community ranking, risk, media sentiment and valuation.

Does the media favor QURE or OVID?

In the previous week, Ovid Therapeutics had 1 more articles in the media than uniQure. MarketBeat recorded 2 mentions for Ovid Therapeutics and 1 mentions for uniQure. uniQure's average media sentiment score of 0.71 beat Ovid Therapeutics' score of 0.00 indicating that Ovid Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
uniQure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ovid Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has stronger valuation & earnings, QURE or OVID?

Ovid Therapeutics has lower revenue, but higher earnings than uniQure. Ovid Therapeutics is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
uniQure	$15.84M	14.10	-$308.48M	-$6.48	-0.72
Ovid Therapeutics	$390K	585.62	-$52.34M	-$0.75	-4.31

Which has more risk & volatility, QURE or OVID?

uniQure has a beta of 0.95, indicating that its stock price is 5% less volatile than the S&P 500. Comparatively, Ovid Therapeutics has a beta of 0.71, indicating that its stock price is 29% less volatile than the S&P 500.

Do institutionals & insiders believe in QURE or OVID?

78.8% of uniQure shares are owned by institutional investors. Comparatively, 72.2% of Ovid Therapeutics shares are owned by institutional investors. 4.1% of uniQure shares are owned by insiders. Comparatively, 12.6% of Ovid Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Does the MarketBeat Community believe in QURE or OVID?

uniQure received 294 more outperform votes than Ovid Therapeutics when rated by MarketBeat users. Likewise, 70.75% of users gave uniQure an outperform vote while only 70.52% of users gave Ovid Therapeutics an outperform vote.

Company	Underperform	Outperform
uniQure	Outperform Votes 636 70.75%	Underperform Votes 263 29.25%
Ovid Therapeutics	Outperform Votes 342 70.52%	Underperform Votes 143 29.48%

Is QURE or OVID more profitable?

uniQure has a net margin of -1,947.09% compared to uniQure's net margin of -13,351.53%. uniQure's return on equity of -49.76% beat Ovid Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
uniQure	-1,947.09%	-99.31%	-37.65%
Ovid Therapeutics	-13,351.53%	-49.76%	-38.16%

Do analysts rate QURE or OVID?

uniQure presently has a consensus price target of $32.00, indicating a potential upside of 585.22%. Ovid Therapeutics has a consensus price target of $9.00, indicating a potential upside of 178.64%. Given Ovid Therapeutics' higher probable upside, research analysts plainly believe uniQure is more favorable than Ovid Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
uniQure	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71
Ovid Therapeutics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

uniQure beats Ovid Therapeutics on 10 of the 18 factors compared between the two stocks.